FPI-1792

N/A

Report date: 2025/11/24 17:27:20

Base Information

Drug NameFPI-1792

Drug Alias NameFPI-1792[225Ac]-TAT

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Actinium > 225Ac +[5]

Mechanisms of ActionIonising radiation emittersInsulin-like growth factor I receptor binders

TargetsInsulin-like growth factor I receptor

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesFusion Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFusion Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A